Abstract
p53 is a key tumor suppressor that plays a critical role in coordinating the response of cells to a diverse range of stress conditions, e.g. oncogenic activation, hypoxia or DNA damage. Induction of cell death by apoptosis in response to stress by p53 is crucial for the prevention of tumor development as well as for the response to anticancer therapy. p53 triggers apoptosis through multiple mechanisms, including mitochondrial and death receptor pathways, cytoskeleton changes, suppression of survival signalling, and induction of hypoxia. Lesions in the p53 pathway occur so frequently in cancer, regardless of patient age or tumor type, that they appear to be part of the life history of a majority of cancer cells. Given an extremely high potency of apoptosis induction by functional p53, it appears that anti-cancer strategies based on p53 reactivation should be efficient and applicable in a wide range of human tumors. Tumor cells are prone to p53-induced apoptosis due to oncogene activation. Therefore it is conceivable that p53-based therapeutic strategies will not require selective targeting of tumor cells.
Keywords: p53, apoptosis, mitochondrial, anti-cancer strategies, hypoxia
Current Cancer Drug Targets
Title: p53: Fighting Cancer
Volume: 4 Issue: 5
Author(s): Galina Selivanova
Affiliation:
Keywords: p53, apoptosis, mitochondrial, anti-cancer strategies, hypoxia
Abstract: p53 is a key tumor suppressor that plays a critical role in coordinating the response of cells to a diverse range of stress conditions, e.g. oncogenic activation, hypoxia or DNA damage. Induction of cell death by apoptosis in response to stress by p53 is crucial for the prevention of tumor development as well as for the response to anticancer therapy. p53 triggers apoptosis through multiple mechanisms, including mitochondrial and death receptor pathways, cytoskeleton changes, suppression of survival signalling, and induction of hypoxia. Lesions in the p53 pathway occur so frequently in cancer, regardless of patient age or tumor type, that they appear to be part of the life history of a majority of cancer cells. Given an extremely high potency of apoptosis induction by functional p53, it appears that anti-cancer strategies based on p53 reactivation should be efficient and applicable in a wide range of human tumors. Tumor cells are prone to p53-induced apoptosis due to oncogene activation. Therefore it is conceivable that p53-based therapeutic strategies will not require selective targeting of tumor cells.
Export Options
About this article
Cite this article as:
Selivanova Galina, p53: Fighting Cancer, Current Cancer Drug Targets 2004; 4 (5) . https://dx.doi.org/10.2174/1568009043332934
DOI https://dx.doi.org/10.2174/1568009043332934 |
Print ISSN 1568-0096 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5576 |
Call for Papers in Thematic Issues
Advances in Cancer Biomarkers and Potential Drug Targets: From Diagnosis to Therapy
Cancer biomarkers play a crucial role in the diagnosis, prognosis, and treatment of cancer. They provide valuable information for cancer detection, risk assessment, treatment selection, and monitoring response to therapy. With advancements in molecular biology and high-throughput technologies, there has been an increasing interest in identifying and characterizing cancer biomarkers ...read more
Innovative Cancer Drug Targets: A New Horizon in Oncology
Cancer remains one of the most challenging diseases, with its complexity and adaptability necessitating continuous research efforts into more effective and targeted therapeutic approaches. Recent years have witnessed significant progress in understanding the molecular and genetic basis of cancer, leading to the identification of novel drug targets. These include, but ...read more
ROLE OF IMMUNE AND GENOTOXIC RESPONSE BIOMARKERS IN TUMOR MICROENVIRONMENT IN CANCER DIAGNOSIS AND TREATMENT
Biological biomarkers have been used in medical research as an indicator of a normal or abnormal process inside the body, or of a disease. Nowadays, various researchers are in process to explore and investigate the biological markers for the early assessment of cancer. DNA Damage response (DDR) pathways and immune ...read more
Targeting the battlefield between host and tumor: basic research and clinical practice on reshaping tumor immune microenvironment
Immune system protects host against malignant tumors through effector cells and molecules. Cancer development and its response to therapy are regulated by inflammation, which either promotes or suppresses cancer progression. Chronic inflammation facilitates cancer progression and treatment resistance, whereas induction of acute inflammatory reactions often lead to anti-cancer immune responses. ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
DTCM-glutarimide Delays Growth and Radiosensitizes Glioblastoma
Anti-Cancer Agents in Medicinal Chemistry Majra Honey Abrogated the Normal and Cancer Cells Proliferation Inhibition by Juniperus procera Extract and Extract/Honey Generated AgNPs
Anti-Cancer Agents in Medicinal Chemistry Obesity and Cardiovascular Physiology: Impact of some Pharmacological Agents
Current Vascular Pharmacology Homeostasis and the Importance for a Balance Between AKT/mTOR Activity and Intracellular Signaling
Current Medicinal Chemistry Editorial (Hot Topic: TRP Channels as Therapeutic Targets)
Current Topics in Medicinal Chemistry Recent Advances in Understanding and Exploiting the Activation of Anthracyclines by Formaldehyde
Current Medicinal Chemistry - Anti-Cancer Agents Perspectives Offered by Single-Domain Antibodies in Clinical Diagnostic of Pediatric Tumors
Current Medicinal Chemistry Exploring the Synthesis and Anticancer Potential of L-Tyrosine-Platinum(II) Hybrid Molecules
Medicinal Chemistry Phosphatidylinositol 3-Kinase Isoforms as Novel Drug Targets
Current Drug Targets Mechanism-based Modulator Discovery for Sirtuin-catalyzed Deacetylation Reaction
Mini-Reviews in Medicinal Chemistry Transcriptionally Targeted Adenovirus Vectors
Current Gene Therapy Anticancer Drug-Induced Immunomodulation and Cancer Therapeutics
Current Cancer Therapy Reviews Discovery of Novel Regulatory Peptides by Reverse Pharmacology: Spotlight on Chemerin and the RF-amide Peptides Metastin and QRFP
Current Protein & Peptide Science Therapeutic Applications of Crocus sativus L. (Saffron): A Review
The Natural Products Journal Development of Specific Radiopharmaceuticals for Infection Imaging by Targeting Infectious Micro-organisms
Current Pharmaceutical Design cAMP-Mediated Regulation of CYP Enzymes and Its Application in Chemotherapy
Drug Metabolism Letters Subject Index to Volume 3
Current Medicinal Chemistry - Anti-Cancer Agents Identification of Novel Anti-inflammatory Agents from Ayurvedic Medicine for Prevention of Chronic Diseases: “Reverse Pharmacology” and “Bedside to Bench” Approach
Current Drug Targets Clinical Molecular Imaging with PET Agents Other than 18F-FDG
Current Pharmaceutical Biotechnology CCL2-CCR2 Signaling in Disease Pathogenesis
Endocrine, Metabolic & Immune Disorders - Drug Targets